Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).
The iron chelating ability and potential toxicity of subcutaneous infusions of the calcium and zinc salts of diethylene triamine penta-acetic acid (DTPA) have been assessed in metabolic balance studies in 2 iron-loaded thalassaemic patients. Infusions of calcium DTPA were locally well tolerated and the drug was as effective as desferrioxamine in mobilising iron. However, daily infusions in the 1st patient also produced symptomatic zinc depletion which could not be controlled by simultaneous oral zinc supplements. Zinc DTPA proved ineffective as an iron chelator, but zinc balance could be maintained in the 2nd patient by combining intermittent (every 4 d) use of calcium DTPA with oral zinc supplements. Combined studies with desferrioxamine and calcium DTPA showed the drugs to have additive effects, probably as a result of the chelation of iron from different body sites.
D000284:Administration, Oral; D000328:Adult; D001205:Ascorbic Acid / Q000627:therapeutic use; D002648:Child; D003676:Deferoxamine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007501:Iron / Q000097:blood / Q000652:urine; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D004369:Pentetic Acid / Q000627:therapeutic use*; D013431:Sulfates / Q000627:therapeutic use; D013789:Thalassemia / Q000097:blood / Q000628:therapy; D065227:Transfusion Reaction; D015032:Zinc / Q000627:therapeutic use; D019287:Zinc Sulfate
D004338:Drug Combinations; D007502:Iron Chelating Agents; D013431:Sulfates; D019287:Zinc Sulfate; D004369:Pentetic Acid; D007501:Iron; D003676:Deferoxamine; D015032:Zinc; D001205:Ascorbic Acid